Monday, May 5, 2014

Hemispherx Biopharma Announces Alferon N Effective Against MERS

Hemispherx Biopharma just announced that one of its advanced stage biological products, Alferon® N, significantly inhibited the replication of the MERS virus in vitro. MERS-CoV is a recently emerged human coronavirus responsible for the lethal pulmonary syndrome known as MERS.  Hemispherx Biopharma Recent testing in laboratories of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has revealed that Alferon® N was inhibitory to MERS-CoV both when used before test cells were exposed to MERS-CoV, as well as after the cells were exposed to the deadly virus.  To read more check out the article on Hemispherx's Website: